ClinicalTrials.gg
CompletedNCT02702011Updated Apr 2, 2018Results posted

Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus

A Phase 2 interventional study of empagliflozin medium dose and empagliflozin low dose in Diabetes Mellitus, Type 1, sponsored by Boehringer Ingelheim. Completed at 4 sites in Japan. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-04-02.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 53 studies in Diabetes Mellitus, Type 1 with a site in Japan — 4 open to participants now, 6 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Japan.

Enrollment
30th of 43
48 · median 243
Started
2016
with 4 others
Phase 2
4 of 53
none open now
Registered
36th of 53
by date
Lead sponsor
1 of 53
Boehringer Ingelheim

Among the 53 studies in Diabetes Mellitus, Type 1 with a site in Japan, this one is the 30th largest by enrollment of the 43 interventional ones that give a count, is one of 5 that started in 2016, is one of 4 in phase 2, and was the 36th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

4 of the 53 studies in Diabetes Mellitus, Type 1 with a site in Japan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 20 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Diabetes Mellitus, Type 1 with a site in Japan, or all of them as a file.
02

Study summary

To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once daily oral doses of empagliflozin in Japanese patients with type 1 diabetes mellitus as adjunctive therapy to insulin.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated written by the date of Visit 1 (screening) in accordance with Good Clinical Practice (GCP) and local legislation
  • Japanese male or female patient receiving insulin for treatment of documented diagnosis of type 1 diabetes mellitus (T1DM) for at least 1 year at the time of Visit 1 (screening).
  • Fasting C-peptide value of \< 0.6 ng/mL at Visit 2 (placebo run-in) measured by the central laboratory
  • Use of, and be willing, based on the investigator's judgment, to continue throughout the duration of the trial Multiple daily injection(MDI) of insulin consisting of at least 1 basal insulin injection and at least 3 daily bolus injections The total daily insulin dose must be>=0.3 U/kg and \<=1.5 U/kg at Visit 1 (screening)
  • of 7.5% to 10.0% at Visit 1 (screening) measured by the central laboratory and provided that the patients HbA1c does not increase by > 0.5% within 3 months before Visit 1 (screening)
  • Based on the investigator's judgment, patient must have a good understanding of his/her disease and how to manage it, and be willing and capable of performing the following study assessments (assessed at Visits 1 to 3 and just before randomization)
  • patient-led management and adjustment of insulin therapy
  • reliable approach to insulin dose adjustment for meals, such as carbohydrate counting
  • reliable and regular home-based blood glucose monitoring
  • recognize the symptoms of DKA (Diabetic Ketoacidosis), and reliably monitor for ketones
  • implementation of an established "sick day" management regimen
  • Age >=20 years and \<=65 years at Visit 1 (screening)
  • (BMI) >=18.5 kg/m2 and\<=35.0 kg/m2 at Visit 1 (screening)
  • Estimated (eGFR) >=60 mL/min/1.73m² and \<=150 mL/min/1.73m² as calculated by Japanese equation based on creatinine measured by the central laboratory at Visit 1 (screening)
  • Compliance with trial drug administration must be between 80% and 120% during the placebo run-in period, to be judged at Visit 4 and before randomization

Exclusion criteria

Exclusion criteria:

  • History of T2DM (Type 2 Diabetes Mellitus), maturity onset diabetes of the young (MODY), pancreatic surgery or chronic pancreatitis
  • Pancreas, pancreatic islet cells or renal transplant recipient
  • T1DM treatment with any other anti-hyperglycaemic drug (e.g., metformin, alpha-glycosidase inhibitors, glucagon-like-peptide 1 (GLP-1) receptor agonists, SGLT-2 (Sodium-Glucose co-transporter-2) inhibitors, pramlintide, inhaled insulin, pre-mixed insulins, etc.) within 3 months except subcutaneous basal and bolus insulin before Visit 1 (screening) or any history of according to the investigator's judgment
  • Occurrence of severe hypoglycemia involving coma and/or seizure that required hospitalization or hypoglycemia-related treatment by an emergency physician or paramedic within 3 months before Visit 1 (screening)
  • Occurrence of DKA within 3 months before Visit 1 (screening) and until randomization at Visit 4 (Day 1)
  • Irregular sleep/wake cycle (e.g., patients who habitually sleep during the day and work during the night) based on the investigator's judgment
  • Acute coronary syndrome (non-STEMI, STEMI, and unstable angina pectoris), stroke or within 3 months before Visit 1 (screening)
  • Diagnosis of severe gastro paresis based on investigator's judgment
  • Diagnosis of brittle diabetes based on the investigator's judgment
  • Indication of liver impairment, defined by serum levels of either (ALT), aspartate transaminase (AST), or alkaline phosphatase above 3 x (ULN) at Visit 1 (screening) as measured by the central laboratory
  • Eating disorders such as bulimia or anorexia nervosa
  • Treatment with anti-obesity drugs (e.g., Mazindol), surgery or aggressive diet regimen leading to unstable body weight (based on the investigator's judgment) 3 months before Visit 1 (screening) and until randomization
  • Treatment with systemic or planned initiation of such therapy at Visit 1 (screening). Inhaled use of corticosteroids (e.g., for asthma/) is acceptable
  • Change in dose of thyroid hormones within 6 weeks before Visit 1 (screening) or planned change or initiation of such a therapy at Visit 1 (screening)
  • Medical history of cancer or treatment for cancer in the last 5 years before Visit 1 (screening). Resected basal cell carcinoma considered cured is exempted
  • Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells (e.g., malaria, babesiosis, hemolytic anemia) at Visit 1 (screening)
  • Pre-menopausal women (last menstruation \<=1 year before ) who:
  • are nursing or pregnant or
  • are of and are not practicing an acceptable method of , or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include tubal ligation, intra uterine devices/systems, oral contraceptives, complete sexual abstinence, double barrier method and vasectomized partner
  • Alcohol or drug abuse within 3 months before Visit 1 (screening) that would interfere with trial participation based on the investigator's judgment
  • Intake of an drug in another trial within 30 days before Visit 1 (screening)
  • Patient not able to understand and comply with study requirements based on the investigator's judgment
  • Any other clinical condition that, based on investigator's judgment, would jeopardise patient safety or would affect the study outcome (e.g. patients who might be at higher risk of developing genital or mycotic infections, patients with chronic viral infections, etc.) during trial participation
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
48 participants (actual)

Study arms

  • Experimental
    empagliflozin low dose

    Drug: empagliflozin low dose

  • Experimental
    empagliflozin medium dose

    Drug: empagliflozin medium dose

  • Experimental
    empagliflozin high dose

    Drug: empagliflozin high dose

  • Placebo comparator
    placebo

    Drug: placebo

Interventions

  • Drugempagliflozin medium dose
  • Drugempagliflozin low dose
  • Drugempagliflozin high dose
  • Drugplacebo
06

What researchers measure

Primary outcomes

  1. Change From Baseline in 24 Hour UGE on Day 7

    Change from baseline in 24 hour urinary glucose excretion on Day 7 calculated as: UGE on Day 7 - UGE on baseline. Baseline is defined as the last observation prior to the first intake of any randomised trial medication.

    Time frame: Baseline and 7 days

07

Results

Posted Apr 2, 2018
Limitations and caveats
A limitation of the current study is its short duration and small sample size. Another limitation of this study was that patients in the placebo group had to go through unnecessary dose adjustments of insulin.

Participant flow

Participant flow — Overall Study
MilestonePlaceboEmpagliflozin 2.5 mgEmpagliflozin 10 mgEmpagliflozin 25 mg
Started11131212
Completed11121212
Not completed0100
Withdrew: Withdrawal by subject0100

Outcome measures

PrimaryChange From Baseline in 24 Hour UGE on Day 7

Change from baseline in 24 hour urinary glucose excretion on Day 7 calculated as: UGE on Day 7 - UGE on baseline. Baseline is defined as the last observation prior to the first intake of any randomised trial medication.

Time frame:
Baseline and 7 days
Reported as:
Least squares mean · gram per 24 hours (g/24 h)
Change From Baseline in 24 Hour UGE on Day 7
gram per 24 hours (g/24 h)PlaceboEmpagliflozin 2.5 mgEmpagliflozin 10 mgEmpagliflozin 25 mg
Change From Baseline in 24 Hour UGE on Day 7-0.46 ± 7.9664.63 ± 7.3180.73 ± 7.6897.64 ± 7.63
Statistical analysis
  • Placebo vs Empagliflozin 2.5 mg · ANCOVA · p = <0.0001 · Mean difference (net): 65.10 · 95% CI 43.29 to 86.90Mean Difference was calculated as: (mean change from baseline in 24 hour UGE at Day 7 in Empagliflozin 2.5 mg group) - (mean change from baseline in 24 hour UGE at Day 7 in Placebo group)
  • Placebo vs Empagliflozin 10 mg · ANCOVA · p = <0.0001 · Mean difference (net): 81.19 · 95% CI 58.80 to 103.58Mean Difference was calculated as: (mean change from baseline in 24 hour UGE at Day 7 in Empagliflozin 10 mg group) - (mean change from baseline in 24 hour UGE at Day 7 in Placebo group)
  • Placebo vs Empagliflozin 25 mg · ANCOVA · p = <0.0001 · Mean difference (net): 98.11 · 95% CI 75.91 to 120.31Mean Difference was calculated as: (mean change from baseline in 24 hour UGE at Day 7 in Empagliflozin 25 mg group) - (mean change from baseline in 24 hour UGE at Day 7 in Placebo group)

Adverse events

Collected over From first drug administration till 7 days after last drug intake; up to 35 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/11 (0%)11/11 (100%)
Empagliflozin 2.5 mg—0/13 (0%)12/13 (92.3%)
Empagliflozin 10 mg—0/12 (0%)12/12 (100%)
Empagliflozin 25 mg—0/12 (0%)12/12 (100%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPlaceboEmpagliflozin 2.5 mgEmpagliflozin 10 mgEmpagliflozin 25 mg
HypoglycaemiaMetabolism and nutrition disorders11/1112/1312/1212/12
Dizziness posturalNervous system disorders1/110/130/120/12
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/110/130/120/12
Abdominal painGastrointestinal disorders1/110/130/120/12
Abdominal pain upperGastrointestinal disorders1/110/130/120/12
Faeces softGastrointestinal disorders1/110/130/120/12
Alanine aminotransferase increasedInvestigations1/110/130/120/12
Vulvovaginal candidiasisInfections and infestations0/111/130/121/12
Decreased appetiteMetabolism and nutrition disorders0/110/131/120/12
HeadacheNervous system disorders0/111/131/120/12

Baseline characteristics

Full Analysis Set (FAS): All patients randomised, treated with at least 1 dose of study drug, who had a baseline Urinary glucose excretion (UGE) (gram (g)/24 hour (h)) and a UGE (g/24 h) on Day 1 or Day 7.

Age, Continuous
Age, Continuous(Years)PlaceboEmpagliflozin 2.5 mgEmpagliflozin 10 mgEmpagliflozin 25 mgTotal
Mean43.9 ± 11.744.2 ± 12.644.5 ± 11.846.6 ± 10.844.8 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEmpagliflozin 2.5 mgEmpagliflozin 10 mgEmpagliflozin 25 mgTotal
Female688426
Male554822
08

Study locations

4 sites
  • Souseikai Hakata Clinic
    Fukuoka, Fukuoka, 812-0025, Japan
  • Nishikumamoto Hospital
    Kumamoto, Kumamoto, 861-4157, Japan
  • Shinjuku Research Park Clinic
    Tokyo, Shinjyuku-ku, 169-0073, Japan
  • SOUSEIKAI Sumida Hospital
    Tokyo, Sumida-ku, 130-0004, Japan
09

References and documents

Publications

  • Shimada A, Hanafusa T, Yasui A, Lee G, Taneda Y, Sarashina A, Shiki K, George J, Soleymanlou N, Marquard J. Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial. Diabetes Obes Metab. 2018 Sep;20(9):2190-2199. doi: 10.1111/dom.13351. Epub 2018 Jun 5. PubMed 29766633 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Sep 2016, 5 months.

Results were first posted in Apr 2018, 1 year 6 months after primary completion.

Of 50 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 33. This study's 5 months is below that.

Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2016
First posted
Mar 8, 2016
StartActual
Mar 20, 2016
Primary completionActual
Sep 5, 2016
CompletionActual
Oct 3, 2016
Results first posted
Apr 2, 2018
Last update
Apr 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02702011
Responsible party
Sponsor
First posted
Mar 8, 2016
Start date
Mar 20, 2016
Primary completion
Sep 5, 2016
Completion
Oct 3, 2016
Results posted
Apr 2, 2018
Last update
Apr 2, 2018

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion